CDC73/HRPT2 CpG island hypermethylation and mutation of 5′-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors

Endocrine-Related Cancer

Volumn 17, Issue 1, 2010, Pages 273-282

  Hahn, Michael A ^a   Howell, Viive M ^a   Gill, Anthony J ^a   Clarkson, Adele ^a   Weaire Buchanan, Graham ^a   Robinson, Bruce G ^a   Delbridge, Leigh ^a   Gimm, Oliver ^b   Schmitt, Wolfgang D ^c   Teh, Bin T ^d   Marsh, Deborah J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HRPT2 PROTEIN; PARAFIBROMIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ALLELE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; EXON; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN TISSUE; METHYLATION; NUCLEOTIDE SEQUENCE; PARATHYROID TUMOR; PROTEIN EXPRESSION; WILD TYPE;

5' UNTRANSLATED REGIONS; ADENOMA; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 77449138903     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0291     Document Type: Article

References (44)

1. Alvarez-Nunez F, Bussaglia E, Mauricio D, Ybarra J, Vilar M, Lerma E, de Leiva A & Matias-Guiu X 2006 PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16 17-23.
2. Astuti D, Morris M, Krona C, Abel F, Gentle D, Martinsson T, Kogner P, Neumann HP, Voutilainen R, Eng C et al. 2004 Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. British Journal of Cancer 91 1835-1841.
3. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A et al. 2006 Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Research 66 2000-2011.
4. Bender BU, Gutsche M, Glasker S, Muller B, Kirste G, Eng C & Neumann HP 2000 Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 85 4568-4574.
5. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, Conceicao Pereira M, Davie MW, Dudley N et al. 2006 Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clinical Endocrinology 64 299-306.
6. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C et al. 2000 VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Research 60 1942-1948.
7. Carling T, Du Y, Fang W, Correa P & Huang S 2003 Intragenic allelic loss and promoter hypermethylation of the RIZ1 tumor suppressor gene in parathyroid tumors and pheochromocytomas. Surgery 134 932-940.
8. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD et al. 2002 HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nature Genetics 32 676-680.
9. Cascon A, Ruiz-Llorente S, Fraga MF, Leton R, Telleria D, Sastre J, Diez JJ, Martinez Diaz-Guerra G, Diaz Perez JA, Benitez J et al. 2004 Genetic and epigenetic profile of sporadic pheochromocytomas. Journal of Medical Genetics 41 e30.
10. Cavallari I, Silic-Benussi M, Rende F, Martines A, Fogar P, Basso D, Vella MD, Pedrazzoli S, Herman JG, Chieco-Bianchi L et al. 2009 Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma. Genes, Chromosomes & Cancer 48 383-396.
11. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzerro E, Colussi G, Berti P et al. 2004 Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. Journal of Clinical Endocrinology and Metabolism 89 5583-5591.
12. Cetani F, Pardi E, Ambrogini E, Viacava P, Borsari S, Lemmi M, Cianferotti L, Miccoli P, Pinchera A, Arnold A et al. 2007 Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. Endocrine-Related Cancer 14 493-499.
13. Clifford SC, Prowse AH, Affara NA, Buys CH & Maher ER 1998 Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes, Chromosomes & Cancer 22 200-209.
14. Corbetta S, Vaira V, Guarnieri V, Scillitani A, Eller-Vainicher C, Ferrero S, Vicentini L, Chiodini I, Bisceglia M, Beck-Peccoz P et al. 2009 Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocrine-Related Cancer 17 135-146.
15. Dammann R, Schagdarsurengin U, Seidel C, Trumpler C, Hoang-Vu C, Gimm O, Dralle H, Pfeifer GP & Brauckhoff M 2005 Frequent promoter methylation of tumor-related genes in sporadic and men2-associated pheochromocytomas. Experimental and Clinical Endocrinology & Diabetes 113 1-7.
16. Esteller M 2007 Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews. Genetics 8 286-298.
17. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, Cantos B, Provencio M, Espana P & Bonilla F 2004 Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes, Chromosomes & Cancer 41 117-124.
18. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM & Marsh DJ 2006 Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndromerelated adenomas from sporadic parathyroid adenomas and hyperplasias. American Journal of Surgical Pathology 30 1140-1149.
19. Glasker S, Bender BU, Apel TW, van Velthoven V, Mulligan LM, Zentner J & Neumann HP 2001 Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. Journal of Neurology, Neurosurgery, and Psychiatry 70 644-648.
20. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM & Boland CR 2004 Frequent inactivation of PTEN by promoter hypermethylation inmicrosatellite instability-high sporadic colorectal cancers. Cancer Research 64 3014-3021.
21. Haven CJ, Howell VM, Eilers PH, Dunne R, Takahashi M, van Puijenbroek M, Furge K, Kievit J, Tan MH, Fleuren GJ et al. 2004 Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Research 64 7405-7411.
22. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM et al. 1994 Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. PNAS 91 9700-9704.
23. Hewitt KM, Sharma PK, Samowitz W & Hobbs M 2007 Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Annals of Otology, Rhinology, and Laryngology 116 928-933.
24. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J et al. 2003 HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. Journal of Medical Genetics 40 657-663.
25. Kelly TG, Shattuck TM, Reyes-Mugica M, Stewart AF, Simonds WF, Udelsman R, Arnold A & Carpenter TO 2006 Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. Journal of Bone and Mineral Research 21 1666-1671.
26. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH & Bose S 2004 PTEN promoter is methylated in a proportion of invasive breast cancers. International Journal of Cancer 112 407-410.
27. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, Moriyama M, Kobayashi K, Sakai N, Kaneko S et al. 2002 Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes, Chromosomes & Cancer 34 58-68.
28. Krebs LJ, Shattuck TM & Arnold A 2005 HRPT2 mutational analysis of typical sporadic parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 90 5015-5017.
29. Marsh D & Zori R 2002 Genetic insights into familial cancers - update and recent discoveries. Cancer Letters 181 125-164.
30. Marsh DJ, Hahn MA, Howell VM & Gill AJ 2007 Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opinion on Medical Diagnostics 1 377-392.
31. Masi G, Barzon L, Iacobone M, Viel G, Porzionato A, Macchi V, De Caro R, Favia G & Palu G 2008 Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocrine-Related Cancer 15 1115-1126.
32. Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki Y, Mizukoshi T, Yamashita Y, Sakurai A, Suzuki S, Beniko M et al. 2006 Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism- jaw tumour syndrome. Clinical Endocrinology 65 9-16.
33. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 458-460.
34. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V et al. 2008 Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clinical Cancer Research 14 4726-4734.
35. Ross JS, Carlson JA & Brock G 2007 miRNA: the new gene silencer. American Journal of Clinical Pathology 128 830-836.
36. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA & Das S 2001 PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. International Journal of Cancer 91 22-26.
37. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C & Dammann R 2006 CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16 633-642.
38. Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD et al. 2003 Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. New England Journal of Medicine 349 1722-1729.
39. Smits KM, Schouten LJ, van Dijk BA, Hulsbergen-van de Kaa CA, Wouters KA, Oosterwijk E, van Engeland M & van den Brandt PA 2008 Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clinical Cancer Research 14 782-787.
40. Takeuchi H, Greep NC, Hoon DS, Giuliano AE, Hansen NM, Umetani N & Singer FR 2007 Hypermethylation of adenosine triphosphate-binding cassette transporter genes in primary hyperparathyroidism and its effect on sestamibi imaging. Journal of Clinical Endocrinology and Metabolism 92 1785-1790.
41. Tse JY, Wong JH, Lo KW, Poon WS, Huang DP & Ng HK 1997 Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. American Journal of Clinical Pathology 107 459-466.
42. Zhao J, Yart A, Frigerio S, Perren A, Schraml P, Weisstanner C, Stallmach T, Krek W & Moch H 2007 Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene 26 3440-3449.
43. Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, Dasouki M, Feldman GL, Greenberg LA, Ivanovich J et al. 2003 Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. American Journal of Human Genetics 73 404-411.
44. Zysman MA, Chapman WB & Bapat B 2002 Considerations when analyzing the methylation status of PTEN tumor suppressor gene. American Journal of Pathology 160 795-800.